<DOC>
	<DOC>NCT00947440</DOC>
	<brief_summary>The purpose of this study is to assess the bioavailability, safety, tolerability and pharmacokinetics of two tablet formulations as compared to the capsule formulation suspended in liquid.</brief_summary>
	<brief_title>Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation</brief_title>
	<detailed_description>A single-dose, three period, complete cross-over study to evaluate the relative bioavailability, pharmacokinetics, safety and tolerability of two candidate tablet formulations of ABT-072 when compared to that of the original capsule formulation suspended in liquid as a reference.</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Overall healthy subjects, nonchildbearing females included. Use of any medications (prescription and overthecounter), vitamins, or herbal supplements within the 2week period prior to the first dose of study drug administration or within 10 halflives of the respective medication, whichever is longer. Pregnant or breastfeeding female. Positive test result for hepatitis A virus immunoglobulin M (HAVIgM), hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or HIV antibodies (HIV Ab). Positive screen for drugs of abuse, alcohol, or cotinine. Clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder. Use of tobacco or nicotinecontaining products within the 6month period preceding study drug administration.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Bioavailability</keyword>
</DOC>